University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention.

Mahmoudi, M and Waksman, R (2012) Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention. Minerva Cardioangiol, 60 (1). pp. 95-100.

Full text not available from this repository.

Abstract

Percutaneous coronary intervention (PCI) is currently the standard of care for patients presenting with acute coronary syndrome (ACS), as well those patients with "stable" angina who have failed medical therapy in whom PCI is an acceptable alternative to surgical revascularization. The aim of adjunctive antiplatelet and antithrombotic therapy during PCI is to alleviate the risks associated with platelet activation and aggregation, iatrogenic plaque rupture, and thrombus formation during. The aim of this review is to summarize the evidence that has emerged from the randomized studies comparing a strategy combining heparin and a glycoprotein IIb/IIIa inhibitor (GPI) with that of bivalirudin in patients undergoing elective and urgent PCI.

Item Type: Article
Authors :
NameEmailORCID
Mahmoudi, Mm.mahmoudi@surrey.ac.ukUNSPECIFIED
Waksman, RUNSPECIFIEDUNSPECIFIED
Date : February 2012
Uncontrolled Keywords : Acute Coronary Syndrome, Angioplasty, Balloon, Coronary, Antithrombins, Drug Therapy, Combination, Heparin, Hirudins, Humans, Peptide Fragments, Platelet Glycoprotein GPIIb-IIIa Complex, Postoperative Complications, Recombinant Proteins
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 09:46
Last Modified : 17 May 2017 09:46
URI: http://epubs.surrey.ac.uk/id/eprint/825096

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800